TY - JOUR
T1 - Molecular pathology testing for non-small cell lung cancer
T2 - an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders
AU - Dufraing, Kelly
AU - Van Casteren, Kaat
AU - Breyne, Joke
AU - D’Haene, Nicky
AU - Van Campenhout, Claude
AU - Vander Borght, Sara
AU - Zwaenepoel, Karen
AU - Rouleau, Etienne
AU - Schuuring, Ed
AU - von der Thüsen, Jan
AU - Dequeker, Elisabeth
N1 - Funding Information:
ES received honoraria for consultancy/advisory board from AstraZeneca, Roche, Pfizer, Bayer, Novartis, BMS, MSD/Merck, BioRad, Illumina, Ageno BioSciences, Janssen Cilag (Johnson&Johnson), BioCartis; speaker’s fee AstraZeneca, Roche, Pfizer, Novartis, BioRad, Illumina, Ageno BioSciences, BioCartis; (unrestricted) grants from Boehringer Ingelheim, BMS, Biocartis, BioRad, Ageno BioSciences and Roche (All outside the submitted work and fees to UMCG). JvdT is a member of the advisory boards of BMS, MSD and Roche. EDQ received a research grant from AstraZeneca. KD, KvC, JB, NDH, CVC, SVB, ER and KZ have nothing to declare.
Funding Information:
The authors wish to thank the laboratories which participated in the laboratory visits, the ESP Lung EQA scheme of 2019 and the Gen&Tiss scheme of 2018-2019. In addition, dr. Cleo Keppens, dr. Inne Nauwelaers, prof. dr. Patrick Pauwels, prof. dr. Ales Ryska, prof. dr. Izidor Kern, dr. Federica Pezzuto, dr. Alexandre Harlé, dr. Aude Lamy and dr. Ludovic Lacroix are thanked for their expertise as an assessor of the EQA schemes and dr. Raed Al Dieri as the general direct of the ESP. We are grateful for the financial support provided by AstraZeneca Belgium Nv.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test conclusions to this knowledge and regulations.Methods: This study consisted of two components; 1) checking the presence of pre-defined elements (administrative and key for therapy-choice) on completed requests and corresponding reports in Belgian laboratories, both for tissue- and liquid biopsy (LB)-testing and b) opinion analysis from Belgian pathologists/molecular biologists and clinicians during national pathology/oncology meetings.Results: Data from 4 out of 6 Belgian laboratories with ISO-accreditation for LB-testing were analyzed, of which 75% were university hospitals. On the scored requests (N = 4), 12 out of 19 ISO-required elements were present for tissue and 11 for LB-testing. Especially relevant patient history, such as line of therapy (for LB), tumor histology and the reason for testing were lacking. Similarly, 11 and 9 out of 18 elements were present in the reports (N = 4) for tissue and LB, respectively.Elements that pathologists/molecular biologists (N = 18) were missing on the request were the initial activating mutation, previous therapies, a clinical question and testing-related information. For reporting, an item considered important by both groups is the clinical interpretation of the test result. In addition, clinicians (N = 28) indicated that they also wish to read the percentage of neoplastic cells.Conclusions: Communication flows between the laboratory and the clinician, together with possible pitfalls were identified. Based on the study results, templates for complete requesting and reporting were proposed.
AB - Background: For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test conclusions to this knowledge and regulations.Methods: This study consisted of two components; 1) checking the presence of pre-defined elements (administrative and key for therapy-choice) on completed requests and corresponding reports in Belgian laboratories, both for tissue- and liquid biopsy (LB)-testing and b) opinion analysis from Belgian pathologists/molecular biologists and clinicians during national pathology/oncology meetings.Results: Data from 4 out of 6 Belgian laboratories with ISO-accreditation for LB-testing were analyzed, of which 75% were university hospitals. On the scored requests (N = 4), 12 out of 19 ISO-required elements were present for tissue and 11 for LB-testing. Especially relevant patient history, such as line of therapy (for LB), tumor histology and the reason for testing were lacking. Similarly, 11 and 9 out of 18 elements were present in the reports (N = 4) for tissue and LB, respectively.Elements that pathologists/molecular biologists (N = 18) were missing on the request were the initial activating mutation, previous therapies, a clinical question and testing-related information. For reporting, an item considered important by both groups is the clinical interpretation of the test result. In addition, clinicians (N = 28) indicated that they also wish to read the percentage of neoplastic cells.Conclusions: Communication flows between the laboratory and the clinician, together with possible pitfalls were identified. Based on the study results, templates for complete requesting and reporting were proposed.
KW - Molecular pathology
KW - Non-small-cell lung cancer
KW - Post-analytical phase
KW - Pre-analytical phase
KW - Test report
KW - Test requesting
U2 - 10.1186/s12885-022-09798-5
DO - 10.1186/s12885-022-09798-5
M3 - Article
AN - SCOPUS:85133535899
SN - 1471-2407
VL - 22
JO - BMC Cancer
JF - BMC Cancer
M1 - 736
ER -